Want to see HK:9887 full AI Analyst Report?
9887 Stock Chart & Stats
HK$92.00
--
Market closed
HK$92.00
--
Day’s Range― - ―
52-Week RangeHK$44.72 - HK$97.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)731.14K
Market Cap
HK$14.84B
Enterprise ValueHK$8.66K
Total Cash (Recent Filing)HK$1.72B
Total Debt (Recent Filing)HK$312.13M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding197,670,290
10 Day Avg. Volume688,690
30 Day Avg. Volume731,143
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)6.30
Price to Sales (P/S)40.45
P/FCF Ratio-48.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$98.63Price Target Upside7.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.13
Revenue Forecast (FY)HK$224.08M
Bulls Say, Bears Say
Bulls Say
Balance Sheet RecoveryThe shift from negative to strongly positive equity materially improves financial resilience and provides a stronger capital base. This reduces the balance-sheet stress seen historically, although continued losses could erode that progress.
Emerging Revenue BaseThe appearance of meaningful revenue indicates progress toward commercial activity and creates a foundation for future operating leverage. Sustained revenue generation could improve the business model if product demand becomes more consistent.
Positive EPS GrowthReported positive EPS growth suggests some improvement in per-share performance over the measured period. While the company remains loss-making, continued improvement could support eventual earnings normalization if revenue scales and costs become more controlled.
Bears Say
Persistent Net LossesDeep losses and severely negative margins show that the company has not yet established profitable operating economics. Sustained losses can consume equity, limit strategic flexibility, and require significant improvement in pricing, scale, or cost control.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business is not funding its activities internally. Continued cash burn increases reliance on external financing and could create dilution, refinancing, or liquidity risks before breakeven is reached.
Unreliable Revenue VisibilityLarge revenue fluctuations make demand, commercialization, and future cash generation difficult to forecast. Without a consistent revenue stream, management may struggle to absorb fixed costs, plan investment, or demonstrate that recent sales represent durable growth.
Nanjing Leads Biolabs Co., Ltd. Class H News
9887 FAQ
What was Nanjing Leads Biolabs Co., Ltd. Class H’s price range in the past 12 months?
Nanjing Leads Biolabs Co., Ltd. Class H lowest stock price was HK$44.72 and its highest was HK$97.50 in the past 12 months.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s market cap?
Nanjing Leads Biolabs Co., Ltd. Class H’s market cap is HK$14.84B.
When is Nanjing Leads Biolabs Co., Ltd. Class H’s upcoming earnings report date?
Nanjing Leads Biolabs Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 3 days.
How were Nanjing Leads Biolabs Co., Ltd. Class H’s earnings last quarter?
Nanjing Leads Biolabs Co., Ltd. Class H released its earnings results on Mar 27, 2026. The company reported -HK$0.25 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Nanjing Leads Biolabs Co., Ltd. Class H overvalued?
According to Wall Street analysts Nanjing Leads Biolabs Co., Ltd. Class H’s price is currently Undervalued.
Does Nanjing Leads Biolabs Co., Ltd. Class H pay dividends?
Nanjing Leads Biolabs Co., Ltd. Class H does not currently pay dividends.
What is Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate?
Nanjing Leads Biolabs Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanjing Leads Biolabs Co., Ltd. Class H have?
Nanjing Leads Biolabs Co., Ltd. Class H has 197,670,290 shares outstanding.
What happened to Nanjing Leads Biolabs Co., Ltd. Class H’s price movement after its last earnings report?
Nanjing Leads Biolabs Co., Ltd. Class H reported an EPS of -HK$0.25 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.698%.
Which hedge fund is a major shareholder of Nanjing Leads Biolabs Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9887
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanjing Leads Biolabs Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$98.63 (7.21% Upside)
HK$98.63 (7.21% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
178.51%
Trailing 12-Months
Company Description
Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
9887 Stock 12 Month Forecast
Average Price Target
HK$98.63
▲(7.21% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Viva Biotech Holdings
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―